AbbVie Inc. $ABBV Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 271,024 shares of the company’s stock after selling 4,715 shares during the period. GW&K Investment Management LLC’s holdings in AbbVie were worth $70,897,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. State Street Corp increased its holdings in AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after buying an additional 1,379,232 shares during the last quarter. Fisher Asset Management LLC raised its position in AbbVie by 252.6% in the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after acquiring an additional 23,991,451 shares during the period. Corient Private Wealth LP purchased a new position in AbbVie in the second quarter valued at about $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in AbbVie in the second quarter valued at about $2,905,952,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key AbbVie News

Investors following ABBV have been watching these news items:

  • Positive Sentiment: AbbVie and DISCO Pharmaceuticals agreed to collaborate on next-generation bispecific therapies for solid tumors. DISCO will lead discovery, and AbbVie may exclusively license selected programs. DISCO could receive $40 million upfront and up to about $2.5 billion in milestone payments, making the deal a potential pipeline boost while tying most of the cost to future progress. DISCO and AbbVie sign gated bispecific deal
  • Neutral Sentiment: AbbVie plans to invest more than $200 million to modernize its Barceloneta manufacturing campus in Puerto Rico. The project may support long-term production capabilities, but the announcement does not indicate an immediate earnings contribution. AbbVie Puerto Rico manufacturing investment
  • Negative Sentiment: ABBV weakened despite the partnership news. The potential cancer therapies remain in the discovery and development stage, so clinical, regulatory and timing risks may limit the deal’s near-term value to investors. AbbVie stock dips despite DISCO cancer deal

Insider Buying and Selling

In related news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the transaction, the executive vice president directly owned 83,171 shares in the company, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Scotiabank lifted their price target on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. HSBC upped their price objective on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. The Goldman Sachs Group upped their price objective on AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a research note on Friday, October 23rd. Finally, BMO Capital Markets set a $315.00 price objective on AbbVie in a report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $299.62.

View Our Latest Stock Report on AbbVie

AbbVie Stock Down 0.9%

NYSE ABBV opened at $283.36 on Friday. The company has a market cap of $500.87 billion, a PE ratio of 48.77, a price-to-earnings-growth ratio of 1.30 and a beta of 0.20. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93. The firm’s 50-day simple moving average is $278.40 and its two-hundred day simple moving average is $242.25.

AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.09. The firm had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $1.86 earnings per share. As a group, equities research analysts anticipate that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be issued a $1.82 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.6%. AbbVie’s payout ratio is 125.30%.

AbbVie Company Profile

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Further Reading

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.